Semiconductor nanocrystal-aptamer bioconjugate probes for specific prostate carcinoma cell targeting

Cancer of the prostate affects approximately 1 in 11 men. Current early screening for prostate cancer utilizes digital rectal examinations to detect anomalies in the prostate gland and blood test screenings for upregulated levels of prostate specific antigen (PSA). Many of these tests are invasive and can often be inconclusive as PSA levels may be heightened due to benign factors. Prostate specific membrane antigen (PSMA), a well-characterized integral membrane protein, is expressed in virtually all prostate cancers and often correlates with cancer aggressiveness. Therefore, it may be used as an indicator of cancer growth and metastases. PSMA-specific antibodies have been identified and conjugated to fluorescent markers for cancer cell targeting; however, both the antibodies and markers possess significant limitations in their pharmaceutical and diagnostic value. Here we report the use of semiconductor nanocrystals bioconjugated to PSMA-specific aptamer recognition molecules for prostate carcinoma cell targeting. The nanocrystal/aptamer bioconjugates are small biocompatible probes with the potential for color-tunability for multicolor imaging. Ongoing in vitro and in vivo research seeks to introduce these nanoparticle bioconjugates into medical diagnostics.

[1]  J. Saldanha,et al.  The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: Implications for drug design , 2008, Protein science : a publication of the Protein Society.

[2]  Shouhei Morimoto,et al.  [In-vivo imaging of tumors with protease activated near-infrared fluorescent probes]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[3]  R. Tsien,et al.  Aptamers switch on fluorescence of triphenylmethane dyes. , 2003, Journal of the American Chemical Society.

[4]  J. McIntosh,et al.  Single-strand DNA Aptamers as Probes for Protein Localization in Cells , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  Stephen G. Hickey,et al.  Highly Luminescent Water-Soluble CdTe Quantum Dots , 2003 .

[6]  Nikolai Gaponik,et al.  Labeling of Biocompatible Polymer Microcapsules with Near-Infrared Emitting Nanocrystals , 2003 .

[7]  G. Mize,et al.  Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. , 2003, Biochemistry.

[8]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[9]  Nikolai Gaponik,et al.  THIOL-CAPPING OF CDTE NANOCRYSTALS: AN ALTERNATIVE TO ORGANOMETALLIC SYNTHETIC ROUTES , 2002 .

[10]  Hedi Mattoussi,et al.  Avidin: a natural bridge for quantum dot-antibody conjugates. , 2002, Journal of the American Chemical Society.

[11]  Ira Herskowitz,et al.  The Khd1 protein, which has three KH RNA‐binding motifs, is required for proper localization of ASH1 mRNA in yeast , 2002, The EMBO journal.

[12]  A M Ward,et al.  Prostate specific antigen: biology, biochemistry and available commercial assays , 2001, Annals of clinical biochemistry.

[13]  Peter Mitchell,et al.  Turning the spotlight on cellular imaging , 2001, Nature Biotechnology.

[14]  R Weissleder,et al.  In vivo imaging of gene and cell therapies. , 2001, Experimental hematology.

[15]  S. Nie,et al.  Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules , 2001, Nature Biotechnology.

[16]  Xiaogang Peng,et al.  Formation of high-quality CdTe, CdSe, and CdS nanocrystals using CdO as precursor. , 2001, Journal of the American Chemical Society.

[17]  R. Singer,et al.  She2p is a novel RNA‐binding protein that recruits the Myo4p–She3p complex to ASH1 mRNA , 2000, The EMBO journal.

[18]  J. Matthew Mauro,et al.  Self-Assembly of CdSe−ZnS Quantum Dot Bioconjugates Using an Engineered Recombinant Protein , 2000 .

[19]  K. Kashima,et al.  Immunohistochemical study of the distribution of endogenous biotin and biotin-binding enzymes in ductal structures of salivary gland tumours. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[20]  J. Cowan,et al.  Recognition of a cognate RNA aptamer by neomycin B: quantitative evaluation of hydrogen bonding and electrostatic interactions. , 2000, Nucleic acids research.

[21]  L. Gold,et al.  Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.

[22]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[23]  J. Pevsner,et al.  Detection of endogenous biotin in various tissues: novel functions in the hippocampus and implications for its use in avidin-biotin technology , 1999, Cell and Tissue Research.

[24]  R. Singer,et al.  Localization of ASH1 mRNA particles in living yeast. , 1998, Molecular cell.

[25]  D. Balding,et al.  HLA Sequence Polymorphism and the Origin of Humans , 2006 .

[26]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[27]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[28]  G. Murphy,et al.  Report on the American urologic association/American cancer societyscientific seminar on the detection and treatment of early‐stage prostate cancer , 1994, CA: a cancer journal for clinicians.

[29]  M Yarus,et al.  Three small ribooligonucleotides with specific arginine sites. , 1993, Biochemistry.

[30]  R. Klausner,et al.  A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains , 1992, Cell.

[31]  I. Trowbridge,et al.  Endocytosis and signals for internalization. , 1991, Current opinion in cell biology.

[32]  W. L. Davis,et al.  Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. , 1990, Cancer research.

[33]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[34]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[35]  S. Bhatia,et al.  Probing the Cytotoxicity Of Semiconductor Quantum Dots. , 2004, Nano letters.

[36]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[37]  Sam S. Chang,et al.  The clinical role of prostate-specific membrane antigen (PSMA). , 2002, Urologic oncology.

[38]  John J. Perona,et al.  Tertiary core rearrangements in a tight binding transfer RNA aptamer , 2000, Nature Structural Biology.

[39]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[41]  Rodney T. Miller.  Endogenous Biotin Artifact January 2004 by , 2022 .